The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. The label expansions of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.), as well as the expected approvals of other immune checkpoint inhibitors, will continue to reshape the HER2-negative gastroesophageal cancer therapy market. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, as well as the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca), are poised to expand treatment options for HER2-positive disease. Other therapies are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and will provide novel treatments for these patient subpopulations.
Questions answered
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.